S-1: Allurion Technologies Files for Potential $30 Million Securities Offering

Allurion Technologies, a medical device company focused on weight loss solutions, has filed a registration statement for a potential offering of up to $30 million in common stock, pre-funded warrants, and common warrants.

Summary

• Allurion Technologies has filed a registration statement for a potential offering of up to $30 million in securities.
• The offering includes shares of common stock, pre-funded warrants in lieu of common stock, and common warrants to purchase additional shares.
• Each share of common stock purchased will come with one common warrant, exercisable for one share of common stock at a price to be determined at the time of pricing.
• The common warrants will expire five years from the date of issuance.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits, and are exercisable at a nominal price of $0.0001 per share.
• The offering is being conducted on a reasonable best efforts basis, with Roth Capital Partners, LLC acting as the exclusive placement agent.
• The company intends to use the net proceeds for commercial sales, research and development, working capital, and other general corporate purposes.
• The offering will terminate on a date to be determined, unless the closing occurs prior or the company decides to terminate the offering.
• Allurion's common stock is listed on the NYSE under the symbol ALUR, and the last reported sale price on December 6, 2024 was $0.37.
• The company's existing public warrants are listed on the NYSE under the symbol ALUR WS, and the last reported sale price on December 6, 2024 was $0.035 per warrant.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting facts about the offering without expressing strong positive or negative sentiment. The offering is a necessary step for the company to raise capital, but it also carries risks for investors.

Positives

• The offering provides Allurion with potential capital to fund its commercial sales, research and development, and working capital.
• The inclusion of pre-funded warrants allows for flexibility in managing ownership limits.
• The company has a listing on the NYSE, which provides liquidity for investors.

Negatives

• The offering is on a reasonable best efforts basis, meaning there is no guarantee that the company will raise the full $30 million.
• The offering price may be at a discount to the current market price of the common stock.
• There is no public market for the pre-funded warrants or common warrants offered, and the company does not intend to list them on any exchange.
• The company is an emerging growth company and a smaller reporting company, which means it is subject to reduced public company reporting requirements.

Risks

• The company may not sell all or any of the securities offered, resulting in less capital raised than anticipated.
• The offering price may be at a discount to the current market price of the common stock, which could lead to dilution for existing shareholders.
• There is no public market for the pre-funded warrants or common warrants, and the company does not intend to list them on any exchange.
• The company is an emerging growth company and a smaller reporting company, which means it is subject to reduced public company reporting requirements.
• The company has a limited operating history and may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets.
• The company has a significant amount of debt, which may affect its ability to operate its business and secure additional financing in the future.
• The company may need additional funds to support its operations, and such funding may not be available on acceptable terms, or at all, which would force the company to delay, reduce, or suspend its planned development and commercialization efforts.
• The company's share price may be volatile, and purchasers of its securities could incur substantial losses.
• Purchasers of the securities will experience immediate and substantial dilution as a result of this offering.
• The company will have broad discretion in how it uses the proceeds of this offering and may not use these proceeds effectively, which could affect its results of operations and cause its stock price to decline.

Future Outlook

The company intends to use the net proceeds for commercial sales, research and development, working capital, and other general corporate purposes.

Industry Context

This offering comes as Allurion seeks to expand its reach in the weight loss market, which is a competitive and rapidly evolving industry. The company is positioning itself as a leader in the non-surgical weight loss space.

Comparison to Industry Standards

• The document does not provide specific financial results to compare to industry standards.
• The document does mention that the Allurion Balloon has demonstrated low device or procedure related rates of serious adverse events, which the company believes compare favorably to that of its competitors.
• The document also mentions that the Allurion Balloon is the world's first and only swallowable, Procedureless intragastric balloon for weight loss, which differentiates it from other intragastric balloons that require surgery, endoscopy, or anesthesia for placement and/or removal.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Investors may be subject to market volatility and potential losses.
• The company may be able to expand its operations and develop new products with the capital raised.

Next Steps

• The company will determine the final pricing of the securities.
• The company will enter into securities purchase agreements with investors who choose to do so.
• The company will close the offering and deliver the securities to investors.
• The company will use the net proceeds for its stated purposes.

Keywords

Allurion Technologies, securities offering, common stock, pre-funded warrants, common warrants, Roth Capital Partners, NYSE, ALUR, ALUR WS, medical device, weight loss